In Q2 2024, OrbiMed Advisors held 92 positions worth $4.8B. They initiated 7 new positions and exited 45. Their largest holding was SVA ($340.0M). Portfolio value shrank -3.4% versus the prior quarter.
Frequently asked questions
What stocks did OrbiMed Advisors own in Q2 2024?
OrbiMed Advisors held 92 biotech stocks in their 13F portfolio in Q2 2024. Their top positions include SVA, LLY, EWTX, BSX, ISRG. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was OrbiMed Advisors's portfolio worth in Q2 2024?
OrbiMed Advisors's tracked biotech portfolio was worth $4.8B across 92 positions, with total assets under management of approximately $19B. Portfolio values are based on 13F filings with the SEC.
What did OrbiMed Advisors buy in Q2 2024?
OrbiMed Advisors initiated 7 new positions in Q2 2024, including ITGR, ADCT, CCCC, GPCR, TGTX and 2 more. They also increased 22 existing positions.
What did OrbiMed Advisors sell in Q2 2024?
OrbiMed Advisors fully exited 45 positions in Q2 2024, including NKTR, MREO, NTLA, AMLX, SYRE and 40 more. They also trimmed 18 existing positions.
Is OrbiMed Advisors a biotech fund?
One of the world's largest healthcare-dedicated investment firms, managing assets across public equity, private equity, royalties, and credit. OrbiMed's team of 100+ professionals includes physicians and PhDs covering all healthcare sub-sectors, with particular depth in biotech and pharma.
Want AI analysis, insider signals, and catalyst overlays for OrbiMed Advisors?
View latest OrbiMed Advisors portfolio →